.png)
RECVISUAL/iStock via Getty Images
- AstraZeneca (NASDAQ:AZN) said that new phase 3 data further supports use of its rescue inhaler Airsupra (albuterol/budesonide) instead of using an albuterol inhaler alone.
- Data from the BATURA trial found that patients with mild asthma on Airsupra saw statistically significant
English (US) ·